Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

January 2011 - FRMC

Department

Conference Insider
01/17/2011
Prague—In a meta-analysis of clinical trials evaluating the safety profiles of monotherapeutic treatments, researchers found that patients with early Parkinson’s disease (PD) who were treated with rasagiline had a lower risk for adverse...
Prague—In a meta-analysis of clinical trials evaluating the safety profiles of monotherapeutic treatments, researchers found that patients with early Parkinson’s disease (PD) who were treated with rasagiline had a lower risk for adverse...
Prague—In a meta-analysis of...
01/17/2011
First Report Managed Care
Conference Insider
01/17/2011
A sample of adults ≥30 years of age in the United States with self-reported, doctor-confirmed Parkinson’s disease (PD) found that patients experiencing off-time had worse overall physical and mental well-being than patients who were stable.
A sample of adults ≥30 years of age in the United States with self-reported, doctor-confirmed Parkinson’s disease (PD) found that patients experiencing off-time had worse overall physical and mental well-being than patients who were stable.
A sample of adults ≥30 years of...
01/17/2011
First Report Managed Care
Conference Insider
01/17/2011
In a recent cohort study of 355 patients diagnosed with acute deep vein thrombosis (DVT) at 7 hospitals in Quebec, Canada, researchers found that the average per patient total cost associated with DVT was $5094 (Canadian), with most of the...
In a recent cohort study of 355 patients diagnosed with acute deep vein thrombosis (DVT) at 7 hospitals in Quebec, Canada, researchers found that the average per patient total cost associated with DVT was $5094 (Canadian), with most of the...
In a recent cohort study of 355...
01/17/2011
First Report Managed Care
Conference Insider
01/17/2011
A pooled analysis of two phase 3 randomized, double-dummy studies found that apixaban was more effective than enoxaparin in preventing venous thromboembolism (VTE) after patients underwent hip or knee replacement surgery. 
A pooled analysis of two phase 3 randomized, double-dummy studies found that apixaban was more effective than enoxaparin in preventing venous thromboembolism (VTE) after patients underwent hip or knee replacement surgery. 
A pooled analysis of two phase 3...
01/17/2011
First Report Managed Care
Feature
01/17/2011
Orlando—A pivotal phase 2, single-arm, multicenter study found that brentuximab vedotin was safe and effective in patients with relapsed or refractory Hodgkin lymphoma who had undergone an autologous stem cell transplant (ASCT). Robert Chen,...
Orlando—A pivotal phase 2, single-arm, multicenter study found that brentuximab vedotin was safe and effective in patients with relapsed or refractory Hodgkin lymphoma who had undergone an autologous stem cell transplant (ASCT). Robert Chen,...
Orlando—A pivotal phase 2,...
01/17/2011
First Report Managed Care
01/17/2011
Olrando—Compared with other chemotherapy agents, pixantrone proved more effective in treating patients with relapsed/refractory non-Hodgkin lymphoma (NHL), according to a randomized, controlled, international, multicenter, open-label, phase 3...
Olrando—Compared with other chemotherapy agents, pixantrone proved more effective in treating patients with relapsed/refractory non-Hodgkin lymphoma (NHL), according to a randomized, controlled, international, multicenter, open-label, phase 3...
Olrando—Compared with other...
01/17/2011
First Report Managed Care
Feature
01/17/2011
Orlando—A retrospective claims database analysis found disease progression among patients with follicular non-Hodgkin lymphoma (f-NHL) was associated with a $2647 higher per patient per month (PPPM) cost and higher healthcare utilization...
Orlando—A retrospective claims database analysis found disease progression among patients with follicular non-Hodgkin lymphoma (f-NHL) was associated with a $2647 higher per patient per month (PPPM) cost and higher healthcare utilization...
Orlando—A retrospective claims...
01/17/2011
First Report Managed Care
Feature
01/17/2011
Orlando—A meta-analysis of phase 2 and phase 3 trials found that patients taking defibrotide to treat severe hepatic veno-occlusive disease with multiorgan failure (VOD/MOF) had significantly higher complete response (CR) rates compared with...
Orlando—A meta-analysis of phase 2 and phase 3 trials found that patients taking defibrotide to treat severe hepatic veno-occlusive disease with multiorgan failure (VOD/MOF) had significantly higher complete response (CR) rates compared with...
Orlando—A meta-analysis of phase...
01/17/2011
First Report Managed Care
Feature
01/17/2011
Orlando—According to 24-month follow-up data from a phase 3, randomized, open-label, multicenter trial, 150-mg capsules of nilotinib had better results than imatinib mesylate tablets when treating adult patients with chronic phase, newly...
Orlando—According to 24-month follow-up data from a phase 3, randomized, open-label, multicenter trial, 150-mg capsules of nilotinib had better results than imatinib mesylate tablets when treating adult patients with chronic phase, newly...
Orlando—According to 24-month...
01/17/2011
First Report Managed Care
Feature
01/17/2011
Orlando—In an international, multicenter, randomized phase 3 trial of 462 patients with previously untreated asymptomatic, advanced stage follicular lymphoma, researchers concluded that rituximab significantly improved time to initiation of...
Orlando—In an international, multicenter, randomized phase 3 trial of 462 patients with previously untreated asymptomatic, advanced stage follicular lymphoma, researchers concluded that rituximab significantly improved time to initiation of...
Orlando—In an international,...
01/17/2011
First Report Managed Care

Advertisement

Advertisement

Advertisement